BCG Shortage Info - American Urological Association
Patients with high-risk features (i.e., high-grade T1 with additional risk factors such as concomitant CIS, lymphovascular ... BCG should not be used for patients with low-risk disease.. *Intravesical chemotherapy should be used as the first-line option ... If not available, these patients and other high-risk patients may be given a reduced 1/2 to 1/3 dose, if feasible. ... In the event of BCG supply shortage, maintenance therapy should not be given and BCG naïve patients with high-risk disease ...
Air Travel - AUA Annual Meeting
... putting you at potential risk. Be sure to register and reserve housing through this Website. Learn more. ...
Code of Ethics - American Urological Association
The information provided must include known risks and benefits, costs, reasonable expectations and possible complications, ...
MP03-20: PREDICTORS OF PHEOCHROMOCYTOMA SURGERY OUTCOMES ... ITY CLASSIFICATION SCALE: AN INTERNATIONAL STUDY | AUA University
We identified a novel rare coding variant (rs35356162 of UHRF1BP1: OR=4.332, P=3.62E-07) that increased bladder cancer risk in ... A rare variant of UHRF1BP1, rs35356162, increases bladder cancer risk in Han Chinese populations and UHRF1BP1 acts as a tumor ... Approximately 20 loci have been found to be associated with bladder cancer risk by genome-wide association studies (GWAS), ... Logistic regression was conducted to evaluate single marker association with bladder cancer risk in an additive model. Gene ...
MP12-09: Apparent diffusion coefficient predicts ri ... on active surveillance for prostate cancer (APL - 2018) | AUA University
For men in AS, lower ADC scores are associated with increased risk of upgrading to GG,1 and could be a useful component of risk ... MP12-03: Favorable Intermediate-Risk Prostate Cance ... Low-Risk Patients due to Adverse Pathology (APL - 2018). Open/Close ... Multivariable risk prediction can improve identification of men with higher-grade disease, while also minimizing repeat ... 0.08, p = 0.001), higher proportion of men with low-risk cancer (54% vs. 35%, p = 0.005), and prostate lesions with lower ADC ...
MP34-01: Prevalence and diversity of management of prosta ... ssment (CAPRA) score: A French multicenter study | AUA University
... clinicopathological characteristics required to calculate the dAmico risk group and the Cancer of the Prostate Risk Assessment ... Currently, the French High Authority for Health does not recommend mass screening for prostate cancer (PCa), due to the risk of ... Prevalence and diversity of management of prostate cancer patients classified as low risk using DAmico group or Cancer of the ... Our study is intended to reflect the therapeutic attitudes for the management of patients classified as low risk of progression ...
MP35-15: A 17-Gene Assay Drives High Active Surveillance ... a 1,200 Patient Prospective Observational Trial | AUA University
MP35-15: A 17-Gene Assay Drives High Active Surveillance Persistence in Clinically Low-Risk Prostate Cancer: A 17-Gene Assay ... In NCCN low-risk PCa, 58 (53%) of the 110 patients initially recommended IT changed to AS, and 44 (17%) of the 253 patients ... Men with NCCN® very-low-, low- and low-intermediate-risk PCa were enrolled in a multicenter study of a validated 17-gene tissue ... MP35-15: A 17-Gene Assay Drives High Active Surveillance Persistence in Clinically Low-Risk Prostate Cancer: Open/Close details ...
Fundamentals in Urology Webcast (2022): Session 1: Residency 101 | AUA University
Identify the possible causes of and risk factors for developing hematuria.. *. Determine the process of who, how and why to ...
MP04-10: Use of 5?-reductase inhibitors for benign prosta ... rostate cancer: A French population-based study. | AUA University
Use of 5?-reductase inhibitors for benign prostatic hypertrophy and risk of high-grade prostate cancer: A French population- ... Observational studies with different designs all reported an increased risk for high grade prostate cancer, though not ...
Webinar: Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment ...
Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment (2020) will ... Webinar: Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment ( ... Webinar: Renal Cell Carcinoma: Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment ( ...
MP15-13: Examining Changes in the Urinary Microbiom ... opsy of the Prostate Using 16sRNA Analysis (AM - 2018) | AUA University
MP10-20: Risk Factors for Postoperative Systemic In ... ally Invasive Percutaneous Nephrolithotomy (AM - 2018). Open/Close ... MP10-15: The Impact of Common Urologic Complications on the Risk of a Prosthetic Joint Infection (AM - 2018). Open/Close ... MP10-15: The Impact of Common Urologic Complications on the Risk of a Prosthetic Joint Infection (AM - 2018). Open/Close ... MP10-19: A Predicting Model Based on Risk Factors for Urosepsis after One-phase Percutaneous Nephrolithotomy (AM - 2018). Open/ ...
MP23-20: Probiotics in recurrent UTIs: collective information on commercially available products (APL - 2018) | AUA University
MP10-20: Risk Factors for Postoperative Systemic In ... ally Invasive Percutaneous Nephrolithotomy (APL - 2018). Open/Close ... MP10-15: The Impact of Common Urologic Complications on the Risk of a Prosthetic Joint Infection (APL - 2018). Open/Close ... MP10-19: A Predicting Model Based on Risk Factors for Urosepsis after One-phase Percutaneous Nephrolithotomy (APL - 2018). Open ...
MP15-12: Intestinal Microbiome Shows Altered Divers ... riers of Fluoroquinolone Resistant E. Coli (VM - 2018) | AUA University
MP10-20: Risk Factors for Postoperative Systemic In ... ally Invasive Percutaneous Nephrolithotomy (VM - 2018). Open/Close ... MP10-15: The Impact of Common Urologic Complications on the Risk of a Prosthetic Joint Infection (VM - 2018). Open/Close ... MP10-19: A Predicting Model Based on Risk Factors for Urosepsis after One-phase Percutaneous Nephrolithotomy (VM - 2018). Open/ ...
MP10-16: The impact of acute kidney injury on prognosis in patients with urological sepsis (APL - 2018) | AUA University
MP10-20: Risk Factors for Postoperative Systemic In ... ally Invasive Percutaneous Nephrolithotomy (APL - 2018). Open/Close ... Although urinary tract infections have higher risk to develop AKI, little is known about the influence of AKI on mortality in ... MP10-15: The Impact of Common Urologic Complications on the Risk of a Prosthetic Joint Infection (APL - 2018). Open/Close ... MP10-19: A Predicting Model Based on Risk Factors for Urosepsis after One-phase Percutaneous Nephrolithotomy (APL - 2018). Open ...
MP08-06: Efficiency of bladder wash cytology during ... Analysis in a contemporary patient cohort (VM - 2018) | AUA University
MP08-08: Discharge of low risk non muscle invasive ... ancer guidelines recommendations in the UK (VM - 2018). Open/Close ... MP08-08: Discharge of low risk non muscle invasive ... ancer guidelines recommendations in the UK (VM - 2018). Open/Close ...
Annual Review Course Live Course Only (2022) | AUA University
Staging and Risk Stratification of Muscle Invasive Bladder Cancer. *Multidisciplinary Treatment including Radical Cystectomy, ... Treatment of Non-Seminomatous Germ Cell Tumors (including Controversy Regarding Stage A Management, Risk Factors for Recurrence ...
MP08-15: Correlation between surgeon's experience a ... ts from a multicentric retrospective study (VM - 2018) | AUA University
MP08-08: Discharge of low risk non muscle invasive ... ancer guidelines recommendations in the UK (VM - 2018). Open/Close ... MP08-08: Discharge of low risk non muscle invasive ... ancer guidelines recommendations in the UK (VM - 2018). Open/Close ...
MP14-14: Propensity Score Matched Study to Examine ... agnetic Resonance Imaging of the Prostate (APL - 2018) | AUA University
MP14-11: Predictive Value of PIRADS v2 for Any and ... ostate Biopsy in a High Risk Ethnic Cohort (APL - 2018). Open/Close ...
The Changing Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2020) | AUA...
Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, ... Identification of High Risk Disease and Initial Management of Biochemical Recurrence. Dr. Boorjian. ...
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2021) | AUA...
Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, ... Identification of High Risk Disease and Initial Management of Biochemical Recurrence. Dr. Boorjian. ...
The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion (2021) | AUA University
Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, ... Identification of High Risk Disease and Initial Management of Biochemical Recurrence. Dr. Boorjian. ...
V4-07: Use of Intra-operative Indocyanine Green and Firefly® Technology to Visualize the "Landmark Artery" | AUA University
V4-02: LAPAROSCOPIC RADICAL PROSTATECTOMY IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER. INDOCYANINE GREEN-. Open/Close details ...
Episode 206: Live From AUA2023: Highlights in Advanced Prostate Cancer | AUA University
4. Analyze the risks and benefits of treatment for advanced prostate cancer.. 5. Identify the criteria for genetic and genomic ...
AUA2019 Urologic Care for the Advanced Practice Provider - Virtual Meeting (2019) | AUA University
Risk Management for Urologic Advanced Practice Providers - Debbie Sullivan, PhD, PA-C ...
MP17-03: RECURRENCE RATES FOLLOWING TESTOSTERONE THERAPY ... ARGE CLINICAL COHORT OF MEN WITH PROSTATE CANCER | AUA University
MP17-12: Utility of serial MRI/ultrasound fusion targeted biopsy in men with low risk prostate cancer managed. Open/Close ... MP17-15: Predictors of Transition to Watchful Waiting from Active Surveillance Among men with low-Risk Prosta. Open/Close ... MP17-06: Utility of Oncotype Dx in Men with Intermediate-Risk Prostate Cancer Open/Close details ...
MP27-07: ANTIMICROBIAL PROPHYLAXIS BEFORE URODYNAMIC STUD ... TATEMENT ON URODYNAMIC ANTIMICROBIAL PROPHYLAXIS | AUA University
The first study to verify a symptomatic post-UDS UTI rate and identify possible risk factors for post-UDS symptomatic UTI. This ... However, a retrospective design and a relatively small number of patients in each group of proposed risk factors might cause ... Urodynamic study (UDS) is an invasive ambulatory procedure that carries a risk for urinary tract infection (UTI). SUFU has ... The statement justifies antimicrobial prophylaxis before UDS in patients with certain risk factors. However, most of the ...
MP35-15: A 17-Gene Assay Drives High Active Surveil ... 00 Patient Prospective Observational Trial (VM - 2018) | AUA University
In NCCN low-risk PCa, 58 (53%) of the 110 patients initially recommended IT changed to AS, and 44 (17%) of the 253 patients ... Men with NCCN® very-low-, low- and low-intermediate-risk PCa were enrolled in a multicenter study of a validated 17-gene tissue ... A 17-Gene Assay Drives High Active Surveillance Persistence in Clinically Low-Risk Prostate Cancer: 1 Year Results from a 1,200 ... Incorporation of GPS testing helps guide individualized risk assessment and results in a change of initial disease management ...
Update Series (2016) Lesson 27: Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer | AUA University
Uses, Risks and Outcomes Using Mesh for Intra-abdominal Surgery. *Consequences and Medicinal Uses of Cannabis by Urology ... intermediate and high risk non-muscle invasive bladder cancer. ...
Update Series (2016) Lesson 14: Multiparametric Magnetic Resonance Imaging for Prostate Cancer | AUA University
Uses, Risks and Outcomes Using Mesh for Intra-abdominal Surgery. *Consequences and Medicinal Uses of Cannabis by Urology ...
MP83-01: ElectroMotive Drug Administration (EMDA) o ... bladder cancer: 3 years followup outcomes (APL - 2018) | AUA University
The EMDA®-MMC is a safe and effective tool in the long term conservative treatment of the high-risk NMIBC unresponsive to BCG, ... MP83-04: The challenge of high risk non muscle invasive bladder cancer treatment in elderly patients (APL - 2018). Open/Close ... ElectroMotive Drug Administration (EMDA) of Mitomycin C as first line salvage therapy in high risk "BCG-failure" non muscle ...